2019 AGENDA

Thursday, April 25, 2019
8:00 AM - 8:30 AM REGISTRATION
Welcome Coffee and Networking
8:30 AM - 8:40 AM CHAIRMAN'S OPENING ADDRESS
Eldora Ellison, Director, Sterne Kessler Goldstein & Fox
8:40 AM - 9:00 AM KEYNOTE ADDRESS
Section 101: Are We on The Other Side of the Looking-Glass?
 
David Gindler
Managing Partner
Irell & Manella
9:00 AM - 9:30 AM PANEL DISCUSSION
US Patent Prosecution & Protection Outlook
 
  • The Likely Forward Direction of the US Supreme Court
  • Recent Case Law Round-up: Hearings, Outcomes, Highlights and Lowlights
  • Hatch-Waxman: Implications and Considerations
  • Bayh Dole: Implications and Considerations
  • Is the Inter Partes Review Process Sufficiently Balanced?
Moderator: 
Ha Kung Wong
Partner 
Venable Fitzapatrick
 
 
Panellists:
Ahmed Mousa
Vice President, General Counsel & Corporate Secretary
Pieris Pharmaceuticals
 
John Kirkland 
Director, Intellectual Property
Alkermes
9:30 AM - 9:50 AM EUROPEAN FOCUS

The Future European Patent Landscape 

  • Where are we at Present and to Where are we Carving a Path?      
  • Latest on the Unified Patent Court and the Unitary Patent System
  • Ideas on Brexit Anyone?
  • Supplementary Protection Certificates Status Overview
Michael Pears
Partner, Biotechnology Patent Department
Potter Clarkson

&

Nick McDonald
Partner, Dispute Resolution and Commercial Department
Potter Clarkson
9:50 AM - 10:05 AM CHINA FOCUS

Protection of Antibodies in China  

Gesheng Huang
Partner
Zhongi Law Office
10:05 AM - 10:35 AM PANEL DISCUSSION

Best Practice In Patenting Precision Medicine 

  • What are the likely precision medicine implications of the Vanda Pharms. Inc. v. West-Ward Pharms. Int’l Ltd. decision in 2018?
  • How might the Advancing Access to Precision Medicine (H.R. 5062), 21st Century Cures and Verifying Accurate, Leading-edge IVCT Development (VALID) Acts, encourage/impact the patent precision medicine landscape?
  • Should the patent eligibility of diagnostic method claims and primer tools issue of the Roche Molecular Systems, Inc. v Cepheid decision be revisited?
  • Will the Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics decision continue to limit the patentability of inventions based on products found in nature?
  • What are possible strategies to successfully patent artificial intelligence-based inventions for precision medicine?

Panellists: 

John Sninsky
Chief Scientific Officer
CareDx
 
Shilpi Banerjee
Chief Intellectual Property Counsel
Memorial Sloan Kettering Cancer Center
10:35 AM - 11:00 AM BREAK

Morning Coffee and Networking in the Exhibition Hall

11:20 AM - 11:50 AM PANEL DISCUSSION

Supplementary Protection Certificates: SPC Global Availability in Light of the Latest Case Law: How are the SPC Regulations Applied and Enforced Across Different Jurisdictions?

Moderator:

Beverley Moore
Partner
Borden Ladner Gervais

 

Panellists:

Sara Citrowske
Patent Counsel
Boston Scientific
11:30 AM - 12:00 PM PANEL DISCUSSION
Biologics and Biosimilars
 
  • Why do the Differences Between Biosimilars and Generics Matter?
  • Do Biologics Necessitate Date Exclusivity Protection?
  • How do we Ensure Effective Protection for Antibodies?
Moderator:
 
Rolando Medina
Partner
Choate Hall & Stewart
12:00 PM - 12:20 PM CANADA FOCUS

Canadian Patent Year in Review and Future Perspective

  • NAFTA 2.0
  • Budget Implementation Act, 2018, No. 2
  • New Patent Rules
  • Notable Patent Cases of 2018
  • Canadian Pharma Developments
David Schwartz
Partner
Smart & Biggar
 
Yoon Kang
Partner
Smart & Biggar
12:20 PM - 12:40 PM PRESENTATION

Plausibility: The threshold for assessing validity of life science patents - a European perspective

  • Plausibility is not a ground of invalidity under the EPC
  • However, it increasingly has a role in the assessment of:
  • Priority
  • Industrial application
  • Obviousness
  • Sufficiency
  • What is the threshold for plausibility and is the right balance being struck?
  • Is data required in the application?
  • Recent court/EPO guidance, including the UK Supreme Court in Warner-Lambert v Actavis (2018)
Zoë Butler
Partner
Powell Gilbert
 
Penny Gilbert
Partner
Powell Gilbert
12:30 PM - 1:45 PM LUNCH BREAK

Lunch and Networking in the Exhibition Hall

1:45 PM ROUNDTABLE(S)
Roundtable Discussion Groups 
Taking part in these discussions offers delegates and speakers the opportunity to focus on topics of specific interest, within a small group. 45 minutes is set aside for each rotation – and delegates may choose two discussion tables. The roundtable discussion groups give delegates even more opportunity to share knowledge and opinion, and ends with a moderator round-up of key findings, providing delegates with an insight into all six topics.
1:45 PM - 2:20 PM ROUNDTABLE
Biologics & Biosimilars
 
Mark Izraelwickz, Partner, Marshall Gerstein & Borun
1:45 PM - 2:20 PM ROUNDTABLE

CAR-T and other Immunotherapies

Lin Hymel, Arent Fox, Partner

1:45 PM - 2:20 PM ROUNDTABLE
Strategies in second medical use cases
 

Emily Hayes, Mewburn Ellis, Partner

Nick Sutcliffe, Mewburn Ellis, Partner

1:45 PM - 2:20 PM ROUNDTABLE

BREXIT: Pragmatic steps for your portfolio, and considerations effect of the SPC & UPC

Sally Shorthose, Partner, Bird & Bird

Patrick Kelleher, Partner, Bird & Bird

1:45 PM - 2:20 PM ROUNDTABLE

Navigating the CRISPR patent and licensing landscape

Claire Irvine, HGF, Partner

1:45 PM - 2:20 PM ROUNDTABLE

Life Sciences Patents Open Clinic: Solving in-house counsel challenges

1:45 PM - 2:20 PM ROUNDTABLE
Venue in Hatch-Waxman Cases after T.C. Heartland
1:45 PM - 2:20 PM ROUNDTABLE

How do we Ensure Effective Protection of Antibodies?

Filko Prugo, Partner, Chair of Life Sciences IP Litigation, Ropes & Gray

Charlotte Jacobsen, Partner, Ropes & Gray 

1:45 PM - 2:20 PM ROUNDTABLE

IP considerations in Personalised Medicine

Brian Slater, Partner and Chair of Life Sciences, Pierce Bainbridge

Conor McDonough, Partner, Pierce Bainbridge

1:45 PM - 2:20 PM ROUNDTABLE

Supplementary Protection Certificates

3:00 PM DISCUSSION GROUP ROUND-UP
Key Findings and Points of Note
3:15 PM - 3:40 PM BREAK
Afternoon Tea and Networking in the Exhibition Hall
3:40 PM - 4:10 PM PANEL DISCUSSION

Addressing Second Medical Use Infringement

  • Recent Key Cases and Overview of Varying Jurisdictions
  • Why we need Global Harmonisation of Patentability
  • What must Generic Manufacturers do where a Second Medical Use Patent is in Force?
  • What Practical Steps must a Second Medical Use Patent Owner take when Infringement is Suspected?

Panellists:

Shahan Islam
Senior Patent Counsel
Pfizer
 
Mary Morry
Counsel
Merck Sharp & Dohme
4:10 PM - 4:25 PM ARROW DECLARATIONS

A Review of Recent Judgements

  • How can parties utilise this litigation tool?
  • When is the relief likely to be useful?
Paul Inman
Partner
Gowling WLG
4:25 PM - 5:00 PM PATENT PORTFOLIO MANAGEMENT

 Best Practice for Efficient IP Prosecution and Licensing

  • What Should Your Approach be for Cost-Effective Global Prosecution
  • Licensing Considerations and Opportunities
5:00 PM - 5:30 PM PANEL DISCUSSION

IP Portfolio Management: In-house Counsel Day-to-Day Challenges in Prosecuting and Enforcing Patents

Moderator:

Chad Davis
Partner
Dechert

 

Panellists:

Linda Nassif (TBC)
Patent Attorney
Allergen
 
Danielle Abramson
VP Intellectual Property & Research
RedHill Biopharma
 
Atabak Royaee
Associate Director & Senior Counsel, IP & EHS
Boehringer Ingelheim Pharmaceuticals
5:30 PM CHAIRMAN'S CLOSING REMARKS & NETWORKING DRINKS
Eldora Ellison, Director, Sterne Kessler Goldstein & Fox